Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADG126 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Adagene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADG126 + pembrolizumab is a combination immunotherapy consisting of ADG126, a fully human anti-CTLA-4 monoclonal antibody utilizing a protease-cleavable masking (SAFEbody) technology for tumor-selective activation, and pembrolizumab, a PD-1 receptor-blocking humanized IgG4 monoclonal antibody. ADG126 is preferentially activated in the tumor microenvironment, leading to enhanced T cell priming via partial CTLA-4 ligand blockade and potent regulatory T cell depletion through antibody-dependent cellular cytotoxicity (ADCC). Pembrolizumab inhibits the PD-1 pathway to restore and sustain anti-tumor immune responses. The combination is being developed for advanced/metastatic solid tumors, particularly metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastasis. Early-phase clinical trials demonstrate manageable toxicity and encouraging efficacy, with improved response rates relative to conventional CTLA-4/PD-1 combinations[1][2][3][4][5].
- Brand names
- Keytruda
- Other names
- ADG126-pembrolizumab combinationADG-126-pembrolizumab combinationADG 126-pembrolizumab combination
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ADG126 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADG126 + pembrolizumab.